A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis. (PubMed, Front Immunol) - Jun 22, 2022 - "We hypothesized that an efficacious drug candidate for antigen-specific therapy in MG should comprise a broad range of these auto-epitopes and be administered in a noninflammatory and tolerogenic context...Further, we did not observe any signs of toxicity or intolerability in animals treated with α1-ECD We conclude that intravenous treatment with α1-ECD is safe and effective in suppressing EAMG. α1-ECD is in preclinical development as a promising new drug candidate for MG."
Journal • CNS Disorders • Immunology • Myasthenia Gravis
|